Yue K - Search Results

1

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.

Jiang Y, Xu J, Yue K, Huang C, Qin M, Chi D, Yu Q, Zhu Y, Hou X, Xu T, Li M, Chou CJ, Li X. Jiang Y, et al. Among authors: yue k. J Med Chem. 2022 Jan 13;65(1):285-302. doi: 10.1021/acs.jmedchem.1c01472. Epub 2021 Dec 23. J Med Chem. 2022. PMID: 34942071

2

Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy.

Yue K, Hou X, Jia G, Zhang L, Zhang J, Tan L, Wang X, Zhang Z, Li P, Xu W, Li X, Jiang Y. Yue K, et al. Bioorg Chem. 2021 Nov;116:105343. doi: 10.1016/j.bioorg.2021.105343. Epub 2021 Sep 11. Bioorg Chem. 2021. PMID: 34544027

3

Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.

Yue K, Qin M, Huang C, James Chou C, Jiang Y, Li X. Yue K, et al. Bioorg Med Chem Lett. 2022 Aug 15;70:128797. doi: 10.1016/j.bmcl.2022.128797. Epub 2022 May 14. Bioorg Med Chem Lett. 2022. PMID: 35580726

4

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.

Yue K, Sun S, Jia G, Qin M, Hou X, Chou CJ, Huang C, Li X. Yue K, et al. J Med Chem. 2022 Sep 22;65(18):12140-12162. doi: 10.1021/acs.jmedchem.2c00853. Epub 2022 Sep 8. J Med Chem. 2022. PMID: 36073117

5

1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates.

Yue K, Xu C, Wang Z, Liu W, Liu C, Xu X, Xing Y, Chen S, Li X, Wan S. Yue K, et al. Bioorg Chem. 2022 Dec;129:106153. doi: 10.1016/j.bioorg.2022.106153. Epub 2022 Sep 28. Bioorg Chem. 2022. PMID: 36194921

6

Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors.

Yan J, Yue K, Fan X, Xu X, Wang J, Qin M, Zhang Q, Hou X, Li X, Wang Y. Yan J, et al. Among authors: yue k. Eur J Med Chem. 2023 Jan 15;246:115004. doi: 10.1016/j.ejmech.2022.115004. Epub 2022 Dec 7. Eur J Med Chem. 2023. PMID: 36516583

7

Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.

Jia G, Qi K, Hou B, Yue K, Xu T, Jiang Y, Li X. Jia G, et al. Among authors: yue k. Eur J Med Chem. 2023 Nov 15;260:115752. doi: 10.1016/j.ejmech.2023.115752. Epub 2023 Aug 23. Eur J Med Chem. 2023. PMID: 37647727

8

Discovery of Novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis.

Sun S, Li Z, Huang C, Liu J, Yu Q, Jiang X, Yue K, Zhao J, Xu T, Liu Y, Li X, Qin C, Jiang Y. Sun S, et al. Among authors: yue k. J Med Chem. 2023 Dec 14;66(23):16141-16167. doi: 10.1021/acs.jmedchem.3c01511. Epub 2023 Nov 29. J Med Chem. 2023. PMID: 38029358

9

HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.

Yue K, Sun S, Liu E, Liu J, Hou B, Qi K, Chou CJ, Jiang Y, Li X. Yue K, et al. Eur J Med Chem. 2024 Feb 15;266:116127. doi: 10.1016/j.ejmech.2024.116127. Epub 2024 Jan 5. Eur J Med Chem. 2024. PMID: 38224650

10

Psammaplin A analogues with modified disulfide bond targeting histone deacetylases: Synthesis and biological evaluation.

Jiang Y, Tang Y, Li Y, Liu L, Yue K, Li X, Qiu P, Yin R, Jiang T. Jiang Y, et al. Among authors: yue k. Eur J Med Chem. 2024 Sep 5;275:116541. doi: 10.1016/j.ejmech.2024.116541. Epub 2024 May 31. Eur J Med Chem. 2024. PMID: 38851056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

572 results

Search Page

Filters